


Please type a plus sign (+) inside this box 

PTO/SB/08A (08-00)

<p>Substitute for form 1449 PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)</p>				Complete if Known	
Sheet 1		of	2	Application Number	10/593,007
				Filing Date	December 2, 2008
				First Named Inventor	Mario CONTORNI
				Group Art Unit	1648
				Examiner Name	Bao Q. Li
				Attorney Docket Number	PAT051746-US-PCT (2300-51746)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	A1	US 6,333,036	B1	Arminjon, et al.	12-25-2001
	A2	US 2003/180316	A1	Boutriau, et al.	09-25-2003
	A3				
	A4				
	A5				
	A6				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ³	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁷
		Office	Number ⁶	Kind Code ⁴ (if known)			
	B1	WO	97/00697	A	Smithkline Beecham Biologicals, S.A.	01-09-1997	
	B2						
	B3						
	B4						
	B5						
	B6						

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ¹
	C1	AMIR, et al., "Immunogenicity And Safety Of A Liquid Combination Of DT-PRP-T Vs. Lyophilized PRP-T Reconstituted With DTP," <i>Vaccine</i> 15(2):149-154 (1997)				
	C2	BLACK, et al., "Safety Of Combined Oligosaccharide Conjugate Haemophilus Influenzae Type b (HbOC) And Whole Cell Diphtheria-Tetanus Toxoids-Pertussis Vaccine In Infancy," <i>Ped Inf Dis J</i> 12(12):981-985 (1993)				
	C3	CAMPBELL, et al., "Standard And Alternative Regimens Of Haemophilus Influenzae Type b Conjugate Vaccine (Polyribosylribitol Phosphate-Tetanus Toxoid Conjugate Vaccine) Elicit Comparable Antibody Avidities In Infants," <i>Pediatr Infect Dis J</i> 21:822-826 (2002)				
	C4	ESKOLA, et al., "Randomised Trial Of The Effect Of Co-Administration With Acellular Pertussis DTP Vaccine On Immunogenicity Of Haemophilus Influenzae Type b Conjugate Vaccine," <i>Lancet</i> 348:1688-1692 (1996)				

Examiner Signature	/Bao Li/	Date Considered	04/11/2010
--------------------	----------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.L./

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/593,007
				Filing Date	December 2, 2008
				First Named Inventor	Mario CONTORNI
				Group Art Unit	1648
				Examiner Name	Bao Q. LI
Sheet	2	of	2	Attorney Docket Number	PAT051746-US-PCT (2300-51746)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	C5	FERNANDEZ, <i>et al.</i> , "Randomized Trial Of The Immunogenicity Of Fractional Dose Regimens Of PRP-T Haemophilus Influenzae Type B Conjugate Vaccine," <i>Am J Trop Med Hyg</i> <u>62</u> (4):485-490 (2000)	
	C6	GUIMARAES, <i>et al.</i> , "Antibody Response To Haemophilus Influenzae Type b Tetanus Conjugate Vaccine With Two Doses Given At 3 And 5 Months Of Age," <i>Int J Infect Dis</i> <u>6</u> :113-117 (2002)	
	C7	KANRA, <i>et al.</i> , "Effect Of Aluminum Adjuvants On Safety And Immunogenicity Of Haemophilus Influenzae Type b-CRM ₁₉₇ Conjugates Vaccine," <i>Pediatr Int</i> <u>45</u> (3):314-318 (2003)	
	C8	LAGOS, <i>et al.</i> , "Economisation Of Vaccination Against Haemophilus Influenzae Type b: A Randomized Trial Of Immunogenicity Of Fractional-Dose And Two-Dose Regimens," <i>Lancet</i> <u>351</u> (9114):1472-1476 (1998)	
	C9	NICOL, <i>et al.</i> , "Haemophilus Influenzae Type b Conjugate Vaccine Diluted Tenfold In Diphteria-Tetanus-Whole Cell Pertussis Vaccine: A Randomized Trial," <i>Pediatr Inf Dis J</i> <u>21</u> (2):138-141 (2002)	
	C10	NOLAN, <i>et al.</i> , "A Combination Of Liquid Hib (PRP-OMPC), Hepatitis B, Diphteria, Tetanus And Whole-Cell Pertussis Vaccine: Controlled Studies Of Immunogenicity And Reactogenicity," <i>Vaccine</i> <u>19</u> (15-16):2127-2137 (2001)	
	C11	PINES, <i>et al.</i> , "New Acellular Pertussis-Containing Paediatric Combined Vaccines," <i>Vaccine</i> <u>17</u> (13-14):1650-1656 (1999)	
	C12	ROBINSON, "DTP-HBOC Diphteria And Tetanus Toxoids And Pertussis Vaccine Adsorbed And Haemophilus B Conjugate Vaccine," <i>Drugs of Today / Medicamentos De Actualidad</i> <u>29</u> (7):463-464 (1993) XP008052438	
	C13	STURGESSION, <i>et al.</i> , "Haemophilus Influenzae Type b Conjugate Vaccine Stability: Catalytic Depolymerization Of PRP In The Presence Of Aluminum Hydroxide," <i>Vaccine</i> <u>17</u> :1169-1178 (1999)	
	C14	TAMM, <i>et al.</i> , "Double-Blind Study Comparing The Immunogenicity Of A Licensed DT _W PHib-CRM197 Conjugate Vaccine (Quattvaxem(TM)) With Three Investigational, Liquid Formulations Using Lower Doses Of Hib-CRM197 Conjugate," <i>Vaccine</i> <u>23</u> (14):1715-1719 (2005)	

Examiner Signature	/Bao Li/	Date Considered	04/11/2010
--------------------	----------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

¹ Applicant is to place a check mark here if English language Translation attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.L./